Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Sultan Qaboos Univ Med J ; 23(2): 256-258, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-37377818

RESUMEN

Primary systemic vasculitis can present with a wide spectrum of manifestations ranging from systemic non-specific features such as fever, malaise, arthralgia and myalgia to specific organ damage. We describe two cases of cholesterol embolisation syndrome and Kaposi sarcoma mimicking primary systemic vasculitis, both of which were characterised by features such as livedo reticularis, blue toe syndrome, a brown purpuric skin rash and positive perinuclear anti-neutrophil cytoplasmic antibodies associated with Kaposi sarcoma. Establishing the right diagnosis was challenging and thus this report aimed to highlight the possible ways to distinguish them from primary systemic vasculitis.


Asunto(s)
Síndrome del Dedo Azul , Livedo Reticularis , Sarcoma de Kaposi , Vasculitis Sistémica , Humanos , Síndrome del Dedo Azul/complicaciones , Sarcoma de Kaposi/diagnóstico , Sarcoma de Kaposi/complicaciones , Livedo Reticularis/etiología , Livedo Reticularis/patología , Vasculitis Sistémica/complicaciones
2.
Neurosurg Rev ; 46(1): 146, 2023 Jun 24.
Artículo en Inglés | MEDLINE | ID: mdl-37354243

RESUMEN

Cranial irradiation is associated with several adverse events such as endocrinopathy, growth retardation, neurocognitive impairment, secondary malignancies, cerebral vasculopathy, and potential stroke. The better side effects profile of proton beam therapy compared with that of photon radiation therapy is due to its physical properties, mainly the sharp dose fall-off after energy deposition in the Bragg peak. Despite the better toxicity profile of proton beam therapy, the risk of  moyamoya syndrome still exists. We conducted a systematic review of the existing literature on moyamoya syndrome after receiving cranial radiation therapy for pediatric brain tumors to investigate the incidence of moyamoya syndrome after receiving photon versus proton radiation therapy. In this review, we report that the incidence of moyamoya syndrome after receiving proton beam therapy is almost double that of photon-induced moyamoya syndrome. Patients who received proton beam therapy for the management of pediatric brain tumors are more likely to develop moyamoya syndrome at the age of less than 5 years. Meanwhile, most patients with proton-induced moyamoya are more likely to be diagnosed within the first 2 years after the completion of their proton beam therapy.


Asunto(s)
Neoplasias Encefálicas , Enfermedad de Moyamoya , Terapia de Protones , Niño , Humanos , Preescolar , Terapia de Protones/efectos adversos , Enfermedad de Moyamoya/epidemiología , Enfermedad de Moyamoya/etiología , Protones , Incidencia , Neoplasias Encefálicas/complicaciones
3.
Cureus ; 13(11): e19529, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34934549

RESUMEN

Vaccine-related erythema nodosum is uncommon, especially after the coronavirus disease 2019 (COVID-19) vaccine. This study presents the first case of the Pfizer vaccine associated with erythema nodosum. A 22-year-old healthy woman presented with a five-day history of several red painful areas with swelling in the lower extremities that started one day after receiving the first dose of Pfizer vaccine. Past medical history, laboratory investigation, and chest radiograph revealed normal results. Erythema nodosum is an immune reaction that manifests as multiple, painful nodules commonly seen on the shin that resolved spontaneously two to eight weeks after the onset. In the absence of laboratory and chest radiograph abnormalities and shortly after receiving the Pfizer vaccine, vaccine-related erythema nodosum is the only possible explanation.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA